Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

about

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report.

P2860

Q49521748-7FF0E0EB-BD88-4C55-BA6E-D69724085F52

P2860

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q36594257

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@ast

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@en

type

Item

label

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@ast

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@en

prefLabel

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@ast

Metachronous primary uterine c ...... advanced lung adenocarcinoma.

@en

P1476

Metachronous primary uterine c ...... d advanced lung adenocarcinoma

@en

P2093

Andrea Misino

http://www.w3.org/2001/XMLSchema#string

Anna Scattone

http://www.w3.org/2001/XMLSchema#string

Annamaria Catino

http://www.w3.org/2001/XMLSchema#string

Antonio Logroscino

http://www.w3.org/2001/XMLSchema#string

Domenico Galetta

http://www.w3.org/2001/XMLSchema#string

Elisabetta Sara Montagna

http://www.w3.org/2001/XMLSchema#string

Giovanni Simone

http://www.w3.org/2001/XMLSchema#string

Lucia Caldarola

http://www.w3.org/2001/XMLSchema#string

Stella Petroni

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

ALK inhibitors in the treatment of advanced NSCLC.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

P304

145-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2016.01.04

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gabriella Serio

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297729881

http://www.w3.org/2001/XMLSchema#string

P698

26958511

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

4758975

http://www.w3.org/2001/XMLSchema#string

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

about

P2860

P2860

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932